Works matching IS 00178748 AND DT 2022 AND VI 62 AND IP 1
Results: 17
Headache: Reflections on 2021 and looking forward to 2022.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 1, doi. 10.1111/head.14252
- Publication type:
- Article
Cancer risk in patients with migraine: A population‐based cohort study in Denmark.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 57, doi. 10.1111/head.14251
- By:
- Publication type:
- Article
Migraine and light: A narrative review.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 4, doi. 10.1111/head.14250
- By:
- Publication type:
- Article
Headache neuroimaging: A survey of current practice, barriers, and facilitators to optimal use.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 36, doi. 10.1111/head.14249
- By:
- Publication type:
- Article
AHS 2021 consensus on integrating new migraine therapies into clinical practice: Isn't our goal choice of best therapy regardless of cost?
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
The 2022 Headache Editorial Board conflict of interest declarations.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 2, doi. 10.1111/head.14246
- Publication type:
- Article
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 106, doi. 10.1111/head.14244
- By:
- Publication type:
- Article
Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 65, doi. 10.1111/head.14234
- By:
- Publication type:
- Article
Prolactin signaling modulates stress‐induced behavioral responses in a preclinical mouse model of migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 11, doi. 10.1111/head.14248
- By:
- Publication type:
- Article
Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 89, doi. 10.1111/head.14229
- By:
- Publication type:
- Article
Intranasal ketamine for acute cluster headache attacks—Results from a proof‐of‐concept open‐label trial.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 26, doi. 10.1111/head.14220
- By:
- Publication type:
- Article
Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 78, doi. 10.1111/head.14218
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 1, doi. 10.1111/head.14155
- Publication type:
- Article
Erratum.
- Published in:
- 2022
- Publication type:
- Correction Notice
Erratum.
- Published in:
- 2022
- Publication type:
- Correction Notice
Erratum.
- Published in:
- 2022
- Publication type:
- Correction Notice